Resources

1 Resources for

biotech drug

Subscribe to this listing via:
RSS
Email

BNET Resources

Why Biogenerics Will Survive Genzyme's Problems: The Food and Drug Administration rejected Genzyme's request to sell a version of its drug Myozyme made in a new factory, a decision some journalists and bloggers insist on casting as a black mark against the very notion of generic biotech drugs. There's just one problem: These...; Tags: FDA, Genzyme Corp., Clinical Trial, Biotech Drug, WSJ Health Blog, Biotech Industry, Biotechnology, Federal Government, Government, David P. Hamilton; Blog posts 2008-04-22

Additional Resources

Cell Therapy Playing an Increasingly Important Role in The Practice of Medicine: DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reportinfo.asp?report_id=39071) has announced the addition of Jain PharmaBiotech "Cell Therapy - Technologies, Markets and Companies" to their offering This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine....; Articles 2008-05-07
Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs: ARLINGTON, Va., May 6 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc. (BULLETIN BOARD: CSBR) , a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, announced today the completion of a Service Agreement with Concordia Pharmaceuticals, Inc. and initiation...; Articles 2008-05-06
REGiMMUNE Raises $8,000,000 in Series B Financing: REGiMMUNE Corporation, aprivately held biopharmaceutical company, announced today that it hasclosed its Series B financing for a total of $8 million U.S. Proceeds fromthe financing will be used to advance the company's lead program, RGI-2001,to human clinical trials for graft versus host disease GvHD. Preclinicaldevelopment for GvHD associated...; Articles 2008-05-06
CrownPeak Helps Pharmaceutical/Biotech Client CV Therapeutics Manage and Distribute Content: CrownPeak, the company defining the futureof content management, today announced that CV Therapeutics, Inc. hasimplemented CrownPeak's award-winning content management system CMS tomanage three of the company's Web sites. CV Therapeutics, abiopharmaceutical company primarily focused on the discovery, developmentand commercialization of new small molecule drugs for the treatment ofcardiovascular diseases, represents...; Articles 2008-05-06

FDA won't seek more tests for Discovery drug: On the first trading day after falling 50 percent, shares of Discovery Laboratories Inc. jumped 31 percent yesterday after the company clarified the status of its experimental respiratory drug for premature infants. The Warrington biotech company said Food and Drug Administration regulators would not require more clinical trials of its...; Articles 2008-05-06
Access Pharmaceuticals Highlighted in Gene Marcial's New Book '7 Commandments of Stock Investing': DALLAS, May 5 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (BULLETIN BOARD: ACCP) announced today that renowned business columnist and author Gene Marcial of BusinessWeek has highlighted Access Pharmaceuticals in his recently released investing book titled "7 Commandments of Stock Investing." In a section pertaining to his sixth...; Articles 2008-05-05
Oncolin Therapeutics Announces That Dr. Randall K. Johnson Has Agreed to Join Its Scientific Advisory Board: HOUSTON -- Oncolin Therapeutics, Inc., (OTCBB:OCOL) is pleased to announce that Dr Randall K. Johnson has agreed to join the Scientific Advisory Board of the company joining a growing number of illustrious oncologists and cancer drug developers. Dr Johnson began his career as section Head of the Experimental Chemotherapy at...; Articles 2008-05-05
Genetic Engineering and Biotechnology News Reports on Early ADMET Use: NEW ROCHELLE, N.Y., May 5 /PRNewswire/ -- Biotech and pharma companies are increasingly utilizing novel technologies to assess the druggability of test compounds early in the development cycle to avoid costly late clinical-stage attrition, according to Genetic Engineering and Biotechnology News GEN (http://www.genengnews.com/). By identifying absorption, distribution, metabolism, excretion,...; Articles 2008-05-05
Cleveland BioLabs Featured in "Gene Marcial's 7 Commandments of Stock Investing": Cleveland BioLabs, Inc. (NASDAQ: CBLI)announced today that the Company has been featured in "Gene Marcial's 7Commandments of Stock Investing," recently published by FT Press. GeneMarcial is a senior writer and columnist at BusinessWeek where he writesthe column "Inside Wall Street." Cleveland BioLabs was cited as one of "several little-known biotechs...; Articles 2008-05-05
WWMR, Inc. Announces New Website to Showcase Research Case Studies: SAN FRANCISCO, May 5 /PRNewswire/ -- Drawing on fifteen years of focused and solution-oriented research, WWMR, Inc. a leading strategic consultancy serving the Biotech, pharmaceutical, medical device and diagnostics industries, announces the launch of their new website showcasing more than 25 Research Case Study summaries. (http://www.wwmr.com/). ...; Articles 2008-05-05
Stryker's Biotech Division Receives FDA Warning Letter: KALAMAZOO, Mich., May 2 /PRNewswire-FirstCall/ -- Stryker Corporation announced today that its Biotech division has received a warning letter from the U. S. Food and Drug Administration FDA related to quality systems and compliance issues at its Hopkinton, Massachusetts location. The warning letter concerns observations made...; Articles 2008-05-02
Canopus BioPharma Engages Pullan Consulting to Commence the Formation of Drug Development and Licensing Partnerships: LOS ANGELES -- Canopus BioPharma, Inc. (OTCPK: CBIA), a biotechnology company developing pharmaceutical products and assay methods for patients suffering from infectious disease, radiation sickness, cancer, and addiction, announced today that it has engaged Pullan Consulting to identify and enter into drug development and licensing partnerships with large pharmaceutical companies....; Articles 2008-05-01
OBS Medical Appoints Chief Medical Officer to Strengthen Pharmaceutical Cardiac Safety Solutions: CARMEL, Ind. -- OBS Medical today announced the appointment of Jay W. Mason, M.D. as Chief Medical Officer. Dr. Jay Mason, a renowned and respected expert in the field of cardiology, will work closely with the OBS Medical research team on innovative clinical algorithms for safer hospitals, safer...; Articles 2008-04-30
Shanghai CRO Service Alliance Adds Clinical Development Capabilities: SHANGHAI, China, April 30 /Xinhua-PRNewswire/ -- Today, Tigermed Consulting Ltd. joins Sundia Meditech, HD BioSciences, and NovaSecta in their CRO Service Alliance CROSA that provides R&D solutions for pharmaceutical and biotech companies. Tigermed's expertise in clinical development complements the existing drug discovery and pharmaceutical development capabilities of the alliance. ...; Articles 2008-04-30
Jonas Ohlsson Appointed CEO/President of Cellectricon: GOTHENBURG, Sweden, April 29 /PRNewswire/ -- Cellectricon, a leading provider of screening solutions for drug discovery, announced today that its board of directors has appointed Jonas Ohlsson as the company's Chief Executive Officer. Mr. Ohlsson brings a solid and highly relevant track record to Cellectricon as the company now...; Articles 2008-04-29
General Physics Corp. of Elkridge unveils biotech courses: General Physics Corp., of Elkridge, a provider of training, e- learning, management consulting and engineering services, announced the availability of a new series of life science compliance online training courses for the pharmaceutical and biotechnical industries. Courses can be accessed through the GPiLearn Rx learning portal, or they can be...; Articles 2008-04-24
Zacks Analyst Blog Highlights: Genomic Health, Teva Pharmaceuticals, Omnicom, MCG Capital and Merrill Lynch: CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Genomic Health Inc. (Nasdaq: GHDX), Teva Pharmaceuticals (Nasdaq: TEVA), Omnicom Group...; Articles 2008-04-24
Embryonic Stem Cells Turned Into Three Types of Heart Cells: A multinational team of researchers has succeeded in turning human embryonic stem cells into three types of human heart muscle cells. When transplanted, the cells also improved heart function in mice. The findings have a number of implications, the most immediate of which would be to use the cells to...; Articles 2008-04-23
Glaxo in $720m deal for US enzyme research biotech: Business News IN BRIEF *GlaxoSmithKline, the UK's biggest drug maker, is paying $720m for an early-stage US biotech company that promises to unlock the secrets of ageing. Sirtris Pharmaceuticals, based in Cambridge, Massachusetts, is working on sirtuins, a recently discovered type of enzyme linked to the ageing...; Articles 2008-04-23

<< Previous
page 1 of 1
Next >>

Resources

biotech drug

BNET Resources

Additional Resources

Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors